Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

3.890 -0.280 (-6.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,548,158
Open 4.200
Bid (Size) 3.820 (700)
Ask (Size) 3.890 (1,100)
Prev. Close 4.170
Today's Range 3.845 - 4.240
52wk Range 2.710 - 7.340
Shares Outstanding 348,875,959
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
From Agenus Bio
Via Business Wire
News headline image
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
From Agenus Inc. & BAP Pharma
Via Business Wire

Performance

YTD
+20.4%
+20.4%
1 Month
+3.2%
+3.2%
3 Month
+34.6%
+34.6%
6 Month
+5.4%
+5.4%
1 Year
+31.0%
+31.0%

More News

Read More
News headline image
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
From Agenus Bio
Via Business Wire
News headline image
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
From Agenus Inc.
Via Business Wire
News headline image
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
From Agenus Bio
Via Business Wire
News headline image
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
From Agenus Bio
Via Business Wire
News headline image
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
From Agenus Bio
Via Business Wire
News headline image
Agenus (AGEN) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host First 2026 Stakeholder Webcast
From Agenus Inc.
Via Business Wire
Thursday's session: top gainers and losers ↗
Via Chartmill
Which stocks are moving on Thursday? ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
From Agenus Inc.
Via Business Wire
News headline image
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
From Agenus Inc.
Via Business Wire
News headline image
Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Agenus (AGEN) Q1 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
From Agenus Inc.
Via Business Wire
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
From Equity Insider
Via GlobeNewswire

Frequently Asked Questions

Is Agenus Inc. - Common Stock publicly traded?
Yes, Agenus Inc. - Common Stock is publicly traded.
What exchange does Agenus Inc. - Common Stock trade on?
Agenus Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Agenus Inc. - Common Stock?
The ticker symbol for Agenus Inc. - Common Stock is AGEN on the Nasdaq Stock Market
What is the current price of Agenus Inc. - Common Stock?
The current price of Agenus Inc. - Common Stock is 3.890
When was Agenus Inc. - Common Stock last traded?
The last trade of Agenus Inc. - Common Stock was at 05/06/26 04:00 PM ET
What is the market capitalization of Agenus Inc. - Common Stock?
The market capitalization of Agenus Inc. - Common Stock is 1.36B
How many shares of Agenus Inc. - Common Stock are outstanding?
Agenus Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.